RE:RE:RE:RE:RE:Are 5.1 million $0.30 May 14, 22 warrants holding down SP?Skier59 ... Quite possible.
One thing's for sure is that with all this Ph. 2 data so far, and being a serious Breakthrough designation and Accelerated Approval program candidate, it's now time that we trade to a more realistic valuation. But for that, we'll have to have more exposure on the US side ands have some finally looking for THE next big thing after the deceiving immunotherapies.
For example, two mere adjuvants to immunotherapy drugs are being valued at 1.3B$US and 680MM$US, ... after failure to deliver clinical results:
Gilead Sciences (GILD.O) last November exercised an option to collaborate with Arcus Biosciences (RCUS.N) (market valuation of 1.3B$US and it is trading at its 52-week low and used to have 3x its current valuation) on the anti-TIGIT drug domvanalimab.
GlaxoSmithKline (GSK.L) in June 2021 struck a licensing deal worth up to 2B$US with iTeos Therapeutics Inc (ITOS.O - market valuation of 680MM$US and it is trading at it 52-week low and used to have 2.5x its current valuation) for an anti-TIGIT candidate.
We destroy, instantly, with any other assistance!